|
|
News Breaks
|
October 26, 2009
|
| 16:36 EDT |  | ICGN |
| theflyonthewall.com: | Icagen reports results of Phase 2a study of Senicapoc | | Icagen reported that in a proof-of-concept, Phase 2a exercise-induced asthma study, senicapoc failed to demonstrate improvement in the primary study endpoints, including maximum decrease in FEV1, time to recovery of FEV1 after exercise and area under the FEV1 curve for sixty minutes. In this double blind placebo-controlled study, 69 patients were randomized to receive either senicapoc at a maintenance dose of 40 mg/day or placebo. All subjects were tested for pulmonary function following a standardized treadmill exercise regimen at baseline, two and four weeks after treatment. Although the company will continue to evaluate the data from this trial, it does not anticipate continuing clinical development of senicapoc at this time. :theflyonthewall.com |
|
|
News For ICGN From The Last 14 Days Check below for free stories on ICGN the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
